Is CorMedix Inc (CRMD) overvalued? · P/E 3.9, rev $43.5M
CorMedix Inc (CRMD) is a biotechnology company listed on US.
This page asks whether CorMedix Inc (CRMD) looks expensive on cached numbers — not a short thesis.
Latest reported CRMD revenue for 2024-12-31 was $43.5M. Net income was -$17.9M. Revenue was up 66363.1% from 2022-12-31 to 2024-12-31. CRMD currently screens at market cap $655.9M and trailing P/E 3.9.
CRMD currently screens at market cap $655.9M and trailing P/E 3.9. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CRMD 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CRMD stock page for the full model, not this heading.
Not investment advice.